Agenus Inc.

Stocks

AGEN

US00847G8042

Market Closed - Nasdaq 16:00:01 2026-09-18 EDT			5-day change	1st Jan Change
7.850 ^USD	+8.73%		+13.11%	+150.00%

09-18	Chardan Initiates Agenus at Buy With $40 Price Target	MT
09-11	Agenus Inc. - Shareholder/Analyst Call

Transcript : Agenus Inc. - Shareholder/Analyst Call

Published on 09/11/2026 at 01:20 am EDT - Modified on 09/11/2026 at 03:06 am EDT

S&P Capital IQ

Presenter Speech
Stefanie Perna-Nacar (Executives)

Good evening, everyone, and thank you for joining us today. My name is Stefanie Nacar, and I'm Chief Communications Officer here at Agenus, and

This article is reserved for our subscribers.

To unlock the article,
subscribe!

Unlimited browsing across the entire site

Access to all news and data

US, Europe, and Asia portfolios

Ad-free reading

Pro Tools : expert screeners, historical financials, PDF reports, investment themes, and earnings transcripts

Latest news about Agenus Inc.

09-18	Chardan Initiates Agenus at Buy With $40 Price Target	MT
09-11	Agenus Inc. - Shareholder/Analyst Call
09-10	Agenus Inc. Presents Three-Year Overall Survival Data for Botensilimab Plus Balstilimab in Recurrent Ovarian Cancer	CI
08-28	Agenus Reports Peer-Reviewed Publication of Mature Phase 1B Results for Botensilimab Plus Balstilimab in Microsatellite-Stable Metastatic Colorectal Cancer	CI
08-26	Agenus Reports Updated Nest Phase 2 Results for Neoadjuvant Botensilimab and Balstilimab in Resectable Colon Cancer	CI
08-11	Agenus Inc. Announces Appointment of Marco Tullio Marcucci as Director and as A Member of Corporate Governance and Nominating Committee, Effective August 5, 2026	CI
08-07	Agenus Files for Resale of Up to 78 Million Shares	MT
08-07	Agenus Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
07-30	B. Riley Adjusts Agenus Price Target to $14 From $8, Maintains Buy Rating	MT
07-14	Agenus Inc. announced that it has received $85 million in funding from RA Capital Management, L.P., Ligand Pharmaceuticals Incorporated, Gunderson Dettmer Stough Villeneuve Franklin & Hachigian, LLP, Investment Arm	CI
07-13	MGM Rises on Takeover Bid; SK Hynix Falls on Memory Pullback \| Stock Movers	MT
07-13	Agenus Inc. - Special Call
07-13	Agenus Signs Deal to Sell Up to $340 Million Worth of Securities; Shares Up Pre-Bell	MT
07-06	Agenus Reports Three-Year Landmark Phase 1b Data For Botensilimab Plus Balstilimab In Refractory Microsatellite-Stable Metastatic Colorectal Cancer Without Active Liver Metastases	CI
07-06	Agenus' Potential Colorectal Cancer Combination Shows 21.2-Month Survival	MT

Chart Agenus Inc.

Duration

Period

AGEN: Dynamic Chart

Company Profile

Sector

More about the company

Income Statement and Estimates

More financial data

Ratings

CCC

More Ratings

EPS Estimates

Revisions to estimates